Evidence map›Paper›PMID 35151614›Full record

ArticleEuropean urology focus2022

Long-term Functional Outcomes and Patient Satisfaction After AdVance and AdVanceXP Male Sling Surgery.

Lina Del Favero, Giovanni Tasso, Yves Deruyver, Manuela Tutolo, Elodie Beels, Charlotte Schillebeeckx, Dirk De Ridder, Frank Van der Aa

Abstract read
PubMed Publisher
In one paragraph

Article in European urology focus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Lina Del FaveroDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Giovanni TassoDepartment of Urology, University of Florence, Carregi Hospital, Florence, Italy.
Yves DeruyverDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Manuela TutoloDivision of Oncology, Unit of Urology, Urological Research Institute, IRCCS, Ospedale San Raffaele, Milan, Italy.
Elodie BeelsDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Charlotte SchillebeeckxDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Dirk De RidderDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Frank Van der AaDepartment of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: frank.vanderaa@uzleuven.be.
KU Leuven · BEIRCCS Ospedale San Raffaele · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransobturator male sling has gained increasing acceptance for the treatment of male urinary incontinence. Several prospective trials have demonstrated the safety and efficacy of the AdVance and AdVanceXP slings.

objectiveTo evaluate long-term functional outcomes after AdVance or AdVanceXP sling implant for non-neurogenic male stress urinary incontinence and identify factors associated with a higher risk for incontinence or decreased satisfaction. DESIGN, SETTING, AND

participantsPatients who underwent AdVance or AdVanceXP implant surgery between June 2007 and April 2018 were retrospectively included in this single-institution, consecutive series. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In April 2020, patients were recontacted to evaluate long-term functional outcomes and satisfaction by standardized, validated questionnaires. RESULTS AND LIMITATIONS: A total of 216 patients were included in this study; 172 of them could be contacted for the assessment of long-term patient reported outcomes. The median follow-up period was 49 mo. Overall social continence (ie, needing no more than one pad per 24 h) at 5-yr follow-up was 66% (confidence interval [CI]: 58-73%). In an ideal population (ie, needing no more than four pads per 24 h and naïve for pelvic radiotherapy, prior incontinence surgery, or urethral stricture surgery), 5-yr social continence rates were markedly better and reached 79% (CI: 69-85%). Overall social continence rates tended to decrease at 10-yr follow-up to 42% (CI: 33-52%). Overall, totally dry rate at 5-yr follow-up was 53% (CI: 46-60%), which again was significantly better in the ideal population (62%, CI: 51-70%). According to the Patient Global Improvement Indices score, 71% (CI: 63-78%) of patients indicated to be satisfied after 5 yr, which improved to 77% (CI: 67-85%) in the ideal patient population. In a multivariate analysis, prior pelvic radiotherapy and previous incontinence or urethral stricture surgery were associated with decreased continence rates and patient satisfaction.

conclusionsIn general, long-term continence rates and patient satisfaction after AdVance and AdVance XP sling surgery are acceptable but deteriorate significantly as time from surgery progresses. Especially patients with a history of pelvic radiotherapy, prior incontinence surgery, or urethral stricture surgery should be counseled properly about their higher risk for sling failure. PATIENT SUMMARY: In this report, we investigated long-term outcomes after Advance and AdvanceXP sling implant for male stress urinary incontinence. We found that, in general, continence and patient satisfaction are acceptable but deteriorate significantly as time from surgery progresses. Patients with previous pelvic radiotherapy, incontinence surgery, or urethral stricture surgery are at higher risk for sling failure.

Indexed as

Suburethral SlingsUrethral StrictureUrinary IncontinenceUrinary Incontinence, StressHumansMalePatient SatisfactionProspective StudiesRetrospective StudiesPatient satisfactionTransobturator male slingUrinary incontinence

Identifiers

PMID35151614
OpenAlexW4211188760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.